|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: VIVITROL
Summary for Tradename: VIVITROL
|
| |||||||||
Clinical Trials for: VIVITROLInjectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI) Status: Completed Condition: Bipolar Disorders; Schizophrenia; Schizoaffective Disorders; Alcohol Dependence Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI) Status: Completed Condition: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Alcohol Dependence Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial. A Free Treatment for Opiate Abuse. Status: Completed Condition: Opiate Dependence; Heroin Dependence Improved Strategies for Outpatient Opioid Detoxification Status: Recruiting Condition: Opioid Dependence Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependents Status: Recruiting Condition: Opiate Dependence Extended-release Naltrexone for Alcohol Dependence in Primary Care Status: Completed Condition: Alcohol Dependence ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence Status: Completed Condition: Alcohol Dependence ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997]) Status: Terminated Condition: Alcoholism; Opiate Dependence ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults Status: Completed Condition: Alcoholism ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids Status: Completed Condition: Opiate Dependence Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR | 021897 | Apr 13, 2006 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR | 021897 | Apr 13, 2006 | RX | Yes | 5,792,477 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR | 021897 | Apr 13, 2006 | RX | Yes | 5,916,598 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR | 021897 | Apr 13, 2006 | RX | Yes | 6,194,006 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc